Therapeutic Advances in Endocrinology and Metabolism (Oct 2021)

Circulating microRNA-194 levels in Chinese patients with diabetic kidney disease: a case–control study

  • Ning Ma,
  • Ning Xu,
  • Dong Yin,
  • Ping Zheng,
  • Weiwei Liu,
  • Guofeng Wang,
  • Yuan Hui,
  • Jiping Zhang,
  • Guanjun Han,
  • Chuanhui Yang,
  • Yiting Chen,
  • Xingbo Cheng,
  • Ming Cheng

DOI
https://doi.org/10.1177/20420188211049615
Journal volume & issue
Vol. 12

Abstract

Read online

Objective: MicroRNAs (miRNAs) regulate gene expression and are involved in diabetic kidney disease (DKD) pathogenesis. We investigated circulating miRNA-194 levels as a biomarker of DKD prevalence and incidence, and the relationship between miRNA-194 and CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP). Methods: We recruited 136 type-2 diabetes mellitus (T2DM) patients at the First People’s Hospital of Lianyungang and 127 healthy individuals. Circulating miRNA-194 and CHOP levels were measured using quantitative reverse transcription qRT-PCR and enzyme-linked immunosorbent assay (ELISA), respectively. Anthropometric and biochemistry measurements were also made. Results: T2DM patients showed higher circulating miRNA-194 ( p = 0.029) and lower circulating CHOP ( p 300 ( p = 0.030, 0.013, <0.001, <0.001, and 0.031, respectively). Conclusion: Circulating miRNA-194 levels could be a novel biomarker for DKD.